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Excessive Perioperative Bleeding
Are Fibrin Monomers and Factor XIII the Missing Link?
PREDICTING perioperative blood loss is traditionally
fraught with great difficulties. Medical history is certainly
crucial in the risk assessment of perioperative blood loss
because it provides information on bleeding history, the
use of antiplatelet drugs, and oral anticoagulation.1 How-
ever, so far there is no laboratory parameter that could
reliably predict perioperative blood loss.2
According to the paper of Korte et al. in this issue of
ANESTHESIOLOGY, there may be hope at least for surgical can-
cer patients.3 In these patients, increased fibrin monomer
levels, suggestive of preoperative coagulation activation,
might be predictive of increased intraoperative blood
loss.3–5 The hypothesis of the authors is that the increase in
fibrin monomer would be due to a preexisting imbalance
between available factor XIII and thrombin.
Thrombin proteolytically cleaves fibrinogen to soluble
fibrin monomers, which are incorporated into a cross-
linked and thus stabilized or nonsoluble fibrin network
in the presence of appropriate amounts of activated
factor XIII. Thrombin also cleaves the A subunit of factor
XIII to generate the enzymatically active factor XIII
(FXIIIa), capable of cross-linking fibrin monomers into a
fibrin strand (fig. 1). The authors hypothesize that a
relative imbalance of thrombin in respect to activatable
factor XIII would result in an accumulation of fibrin
monomers due to the inadequate incorporation of mono-
mers into a stable fibrin network. They further hypoth-
esize that in patients with preoperatively elevated fibrin
monomers, the surgical procedure may lead to an accen-
tuation of the above-described imbalance that may be
associated with increased perioperative blood loss.5,6
The authors tested their hypothesis in a pilot study
with 22 patients. Intraoperative factor XIII substitution
resulted in a reduced decrease of fibrinogen concentra-
tion, a smaller decrease of mean clot firmness in rota-
tional thrombelastography analysis, and reduced blood
loss.
Interestingly, the authors were able to demonstrate in
an earlier study that the developing clot had reduced
maximum clot firmness before the exaggerated surgical
blood loss was observed.4 Most fascinating, by a single
dose of factor XIII (30 U/kg) given 15 min into surgery,
the exaggerated decrease of maximum clot firmness dur-
ing surgery could largely be prevented, and this resulted
in a reduced blood loss.3
A potentially relevant characteristic of the study pop-
ulation of Korte et al. is that patients had pathologically
low factor XIII activities at baseline (approximately 58%
in the verum group vs. 55% in controls). The study
population thus presented with increased fibrin mono-
mer levels and (putatively) acquired factor XIII defi-
ciency. Whether intraoperative factor XIII substitution
will prove useful in patient populations without preex-
isting acquired factor XIII is an open question.
A low factor XIII level has been shown, in keeping
with the results of Korte et al.,3–5 to be a risk factor for
hemorrhage after intracranial7 and coronary artery by-
pass surgery.8 With factor XIII treatment, chest tube
drainage and transfusion needs were indeed reduced in
patients with a normal postoperative factor XIII level.9
The study by Korte et al.3 is highly interesting and
thought-provoking. If the conclusions hold true despite
significant methodological shortcomings and findings
that are difficult to interpret, we may in the future test
patients for fibrin monomers preoperatively, and treat
them if elevated with (a single dose of) factor XIII early
into surgery. At the moment, such a conclusion is pre-
mature because this study has significant limitations.
First, only 22 patients were analyzed. This limits the
power of the study, and the sample size is far too small
to allow any judgment on safety. All procoagulatory
substances may be associated with adverse thrombotic
and thromboembolic events. Second, the study was
powered to show a difference of 30% in maximum clot
firmness and was prematurely terminated because this
threshold was achieved at a planned interim analysis
with a P value of 0.04. Stop rules at planned interim
analyses usually use significantly lower P values to avoid
a false positive result due to an (initial) uneven patient
allocation to the groups by chance and to preserve an
overall two-sided type I error rate of 0.05.10 Therefore,
the question arises whether this trial may have been
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stopped prematurely. Third, estimated blood loss is only
a weak surrogate outcome parameter. Fourth, the spec-
ificity of the fibrin monomer test used in this study with
potential cross-detection of fibrin degradation products
has been debated in the past. In future studies, harder
outcome parameters such as the need for allogenic
blood transfusion should be targeted. In addition, al-
though a higher maximum clot firmness at higher factor
XIII levels can be expected,11 it remains speculative why
fibrinogen would decrease less in factor XIII–treated
patients than in control patients during surgery. One
hypothesis may be that due to a lack of factor XIII
activity fibrin monomers are insufficiently cross-linked,
maximum clot firmness is compromised, and thus bleed-
ing continues with further activation of the coagulation
and fibrinogen consumption.
In conclusion, large multicenter studies in patients at
risk of excessive perioperative blood loss are necessary
to formally test the possible beneficial effect of intraop-
erative use of factor XIII. For the moment, the authors
are to be congratulated for their innovative research and
for having performed a proof-of-principle study in pa-
tients presenting with acquired functional factor XIII
deficiency preoperatively.
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Fig. 1. Roles of thrombin in coagulation
and roles of thrombin and enzymatically
active factor XIII (FXIIIa) in a simplified
model of fibrin strand generation. (A)
According to the cell-based model of co-
agulation, thrombin (IIa) is generated on
the surface of activated cells (left in A) by
FXa-mediated proteolytic cleaveage from
its precursor molecule, prothrombin.
Thrombin (dark gray) is a key enzyme
in coagulation and has multiple func-
tions, including the activation of FXIII to
generate FXIIIa. (B) Fibrinogen mole-
cules comprise three domains: a central
E domain flanked by two D domains.
Fibrinogen is activated to fibrin mono-
mers through the thrombin-mediated
cleavage (dark gray in B) of the fibrin-
opeptides A and B from the E domain.
Fibrinopetide cleavage permits electro-
static interaction (dotted lines) of E do-
mains with D domains of other fibrin
molecules resulting in the formation of a
still soluble fibrin strand. It is only after
FXIIIa (light gray) has cross-linked fi-
brin monomers by covalently linking D
domains of adjacent fibrin monomers
(bold light gray lines) that the strands or
protofibrils become “stabilized” or insol-
uble. Bottom graph (B) modified, with
permission of Elsevier, from Furie B, Fu-
rie BC: Molecular basis of blood coagula-
tion, Hematology: Basic Principles and Practice, 4th edition. Edited by Hoffman R. Philadelphia, Elsevier, 2005, pp 1946. Copyright
© Elsevier 2005.12
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